Pathology of lymphoma in HIV

Current Opinion in Oncology

Volumn 25, Issue 5, 2013, Pages 487-494

  Cesarman, Ethel ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AIDS; Epstein Barr virus; HIV; Kaposi's sarcoma herpesvirus; Lymphoma

Indexed keywords

A20 PROTEIN; ANTIRETROVIRUS AGENT; B LYMPHOCYTE ANTIGEN; B LYMPHOCYTE RECEPTOR; BIOLOGICAL MARKER; CD20 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 2; IMMUNOGLOBULIN; KI 67 ANTIGEN; LATENT MEMBRANE PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR PAX5; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER MORTALITY; CANCER PATIENT; CLASSICAL HODGKIN LYMPHOMA; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC TEST; EPSTEIN BARR VIRUS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INCIDENCE; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; LYMPHOMA; MOLECULARLY TARGETED THERAPY; MOUTH CAVITY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PLASMA CELL; PLASMABLASTIC LYMPHOMA; POLYMORPHIC B CELL LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE; COMPLICATION; MOLECULAR DIAGNOSIS; PATHOLOGY;

HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; MOLECULAR DIAGNOSTIC TECHNIQUES; TUMOR MARKERS, BIOLOGICAL;

EID: 84883254995     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/01.cco.0000432525.70099.a4     Document Type: Review

References (52)

1. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010; 170: 1337-1345.
2. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103: 753-762.
3. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432.
4. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol 2003; 4: 22-29.
5. Gaidano G, Carbone A, Dalla-Favera R. Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. J Natl Cancer Inst Monogr 1998; 5: 95-100.
6. Knowles DM. Neoplastic hematopathology. 2nd ed. Baltimore: Williams and Wilkins; 2001.
7. A review of human carcinogens. Part B: biological agents. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: World Health Organization International Agency for Research on Cancer; 2012. This is an important monograph and is freely available online that very carefully evaluates the epidemiological, biological, and clinical evidence for HIV, EBV, and KSHV, being considered carcinogens\carcinogenic in humans.
8. Breen EC, Hussain SK, Magpantay L, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev 2011; 20: 1303-1314.
9. Hussain SK, Zhu W, Chang SC, et al. Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIVassociated nonhodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 2013; 22: 295-307. This study documents increased levels of a cytokine (CXCL13) in sera from HIV-positive patients preceding a diagnosis of lymphoma, as well as polymorphisms in this gene and its receptor indicating a possible genetic component in AIDS-related NHL.
10. Raphaël M, Said J, Borisch B, et al. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: IARC Press; 2008. pp. 340-342.
11. Said J, Cesarman E, Knowles DM, et al. Lymphadenopathy and the lymphoid neoplasms associated with HIV infection and other causes of immunosuppression. In: Orazi W, Foucar K, Knowles, et al., editors. Knowles' neoplastic hematopathology, 4th ed. Baltimore: Williams and Wilkins; 2013.
12. Cesarman E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett 2011; 305: 163-174.
13. Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 2009; 27: 5039-5048.
14. Dunleavy K, Wilson WH. Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma. J Clin Oncol 2010; 28:e260.
15. Chadburn A, Noy A, Lee JY, et al. Reply to K. Dunleavy et al. J Clin Oncol 2010; 28:e261-e262.
16. Chao C, Silverberg MJ, Martinez-Maza O, et al. Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell lymphoma. Clin Cancer Res 2012; 18: 4702-4712. This study found that the EBV infection status was independently associated with increased mortality in patients with AIDS DLBCL, and may improve clinical patient risk stratification.
17. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
18. Picarsic J, Jaffe R, Mazariegos G, et al. Posttransplant Burkitt lymphoma is a more aggressive and distinct form of posttransplant lymphoproliferative disorder. Cancer 2011; 117: 4540-4550.
19. Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 2010; 116: 5600-5604.
20. Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 1987; 238: 1272-1275.
21. Rabbitts TH, Hamlyn PH, Baer R. Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 1983; 306: 760-765.
22. Burns BF, Wood GS, Dorfman RF. The varied histopathology of lymphadenopathy in the homosexual male. Am J Surg Pathol 1985; 9: 287-297.
23. Bhatia K, Huppi K, Spangler G, et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5: 56-61.
24. Sander CA, Yano T, Clark HM, et al. p53 Mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994-2004.
25. Kluin PM, Harris NL, Stein H, et al. B-cell lymphoma, unclassifiable, with features intermediate betwwwn diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHOclassification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp. 265-266.
26. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-2442.
27. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-2430.
28. Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 2003; 98: 300-309.
29. Carbone A, Gloghini A, Serraino D, Spina M. HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS 2009; 4: 3-10.
30. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated Herpesvirus-like DNA sequences in AIDS-related body cavity-based lymphomas. N Eng J Med 1995; 332: 1186-1191.
31. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcomaassociated herpesvirus. Blood 1996; 88: 645-656.
32. Ashihara E, Shimazaki C, Hirai H, et al. Human herpes virus 8-negative primary effusion lymphoma in a patient with a ventriculoperitoneal shunt tube. Int J Hematol 2001; 74: 327-332.
33. Paner GP, Jensen J, Foreman KE, Reyes CV. HIV and HHV-8 negative primary effusion lymphoma in a patient with hepatitis C virus-related liver cirrhosis. Leuk Lymphoma 2003; 44: 1811-1814.
34. Matsumoto Y, Nomura K, Ueda K, et al. Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab. Leuk Lymphoma 2005; 46: 415-419.
35. Tsagarakis NJ, Argyrou A, Gortzolidis G, et al. Report of an HIV and HHV-8 negative case of primary effusion lymphoma with idiopathic T4 lymphocytopenia. Int J Hematol 2009; 90: 94-98.
36. Saini N, Hochberg EP, Linden EA, et al. HHV8-negative primary effusion lymphoma of B-cell lineage: two cases and a comprehensive review of the literature. Case Rep Oncol Med 2013; 2013: 292301. This is a review of only two cases, but includes a good review of the literature clarifying the features of lymphomas resembling PEL but lacking KSHV infection; importantly, all of these cases with clinical information occurred in patients without HIV, excluding this entity from the list of AIDS-related lymphomas.
37. Chadburn A, Hyjek E, Mathew S, et al. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004; 28: 1401-1416.
38. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997; 89: 1413-1420.
39. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004; 28: 736-747.
40. Gujral S, Shet TM, Kane SV. Morphological spectrum of AIDS-related plasmablastic lymphomas. Indian J Pathol Microbiol 2008; 51: 121-124.
41. Stein H, Harris NL, Campo E. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid ttissues. Lyon, France: IARC Press; 2008. pp. 256-257.
42. Corti M, Villafane MF, Bistmans A, et al. Oral cavity and extra-oral plasmablastic lymphomas in AIDS patients: report of five cases and review of the literature. Int J STD AIDS 2011; 22: 759-763.
43. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 2010; 34: 1686-1694.
44. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95: 1406-1412.
45. Du MQ, Diss TC, Liu H, et al. KSHV-and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002; 100: 3415-3418.
46. Nador RG, Chadburn A, Gundappa G, et al. Human immunodeficiency virus (HIV)-associated polymorphic lymphoproliferative disorders. Am J Surg Pathol 2003; 27: 293-302.
47. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-120. Although this study did not focus specifically on HIV-infected individuals, it identified molecular alterations in ID3 or TCF3 in close to 70% of sporadic Burkitt lymphomas, both in the PI3K/B-cell receptor signaling pathway. This discovery may lead to new therapeutic interventions.
48. Giulino-Roth L, Wang K, MacDonald TY, et al. Targeted genomic sequencing of pediatric Burkitt's lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 2012; 120: 5181-5184. Although not focused on AIDS, this is an idependent study documenting recurrent genetic alterations in pediatric Burkitt's lymphomas, which is distinct in its use of targetted panels and in using archival, formalin-fixed, paraffinembedded tissues.
49. Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt's lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44: 1316-1320. An independent study documenting genetic alterations in Burkitt's lymphomas, although not specifically focused on AIDS.
50. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt's lymphoma. Nat Genet 2012; 44: 1321-1325. An independent study documenting genetic alterations in Burkitt's lymphoma, although not specifically focused on AIDS.
51. Deffenbacher KE, Iqbal J, Liu Z, et al. Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr 2010; 54: 18-26.
52. Giulino L, Mathew S, Ballon G, et al. A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma. Blood 2011; 117: 4852-4854.